{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:52:52Z","timestamp":1776426772158,"version":"3.51.2"},"reference-count":183,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","medical.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.mcna.2016.09.010","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T04:30:17Z","timestamp":1482813017000},"page":"395-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Syndromes of Thrombotic Microangiopathy"],"prefix":"10.1016","volume":"101","author":[{"given":"Joseph J.","family":"Shatzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib1","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood.V96.4.1223","article-title":"How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"96","author":"George","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.blre.2005.02.001","article-title":"Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment","volume":"20","author":"Murrin","year":"2006","journal-title":"Blood Rev"},{"issue":"18","key":"10.1016\/j.mcna.2016.09.010_bib3","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1056\/NEJMcp053024","article-title":"Clinical practice. Thrombotic thrombocytopenic purpura","volume":"354","author":"George","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1445-5994.2008.01637.x","article-title":"Thrombotic thrombocytopenic purpura is associated with a high relapse rate after plasma exchange: a single-centre experience","volume":"39","author":"Frawley","year":"2009","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1365-2141.2003.04049.x","article-title":"Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias","volume":"120","author":"Allford","year":"2003","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.2830470206","article-title":"Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura","volume":"47","author":"Patton","year":"1994","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib7","first-page":"521","article-title":"Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange","volume":"10","author":"Rizzo","year":"2012","journal-title":"Blood Transfus"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1309\/AJCPPNF63FLIORCI","article-title":"Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults","volume":"133","author":"Park","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1016\/j.mcna.2016.09.010_bib9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","article-title":"The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency","volume":"3","author":"Terrell","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"20","key":"10.1016\/j.mcna.2016.09.010_bib10","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10072-010-0465-4","article-title":"Reversible posterior leukoencephalopathy syndrome in a patient with thrombotic thrombocytopenic purpura","volume":"32","author":"Aridon","year":"2011","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1098-1101(1998)13:1<16::AID-JCA3>3.0.CO;2-C","article-title":"Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura","volume":"13","author":"Cohen","year":"1998","journal-title":"J\u00a0Clin Apher"},{"issue":"12","key":"10.1016\/j.mcna.2016.09.010_bib15","first-page":"1108","article-title":"Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption","volume":"114","author":"Neame","year":"1976","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.mcna.2016.09.010_bib16","first-page":"592930","article-title":"Thrombotic thrombocytopenic purpura: a case presenting with acute ischemic colitis","volume":"2013","author":"See","year":"2013","journal-title":"Case Rep Hematol"},{"issue":"21","key":"10.1016\/j.mcna.2016.09.010_bib17","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1182\/blood.V116.21.4683.4683","article-title":"Thrombotic thrombocytopenic purpura induced pancreatitis\u2013 a rare complication","volume":"116","author":"Gotlieb","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000441-200102000-00003","article-title":"Acute respiratory distress syndrome as a major clinical manifestation of thrombotic thrombocytopenic purpura","volume":"321","author":"Chang","year":"2001","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/clc.20731","article-title":"Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience","volume":"33","author":"Gandhi","year":"2010","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1520\/JFS12866J","article-title":"Thrombotic thrombocytopenic purpura causing sudden, unexpected death\u2013a series of eight patients","volume":"35","author":"Bell","year":"1990","journal-title":"J\u00a0Forensic Sci"},{"issue":"23","key":"10.1016\/j.mcna.2016.09.010_bib21","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mcna.2016.09.010_bib22","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"Tsai","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mcna.2016.09.010_bib23","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in\u00a0vivo proteolysis","volume":"87","author":"Furlan","year":"1996","journal-title":"Blood"},{"issue":"6855","key":"10.1016\/j.mcna.2016.09.010_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"issue":"44","key":"10.1016\/j.mcna.2016.09.010_bib25","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura","volume":"276","author":"Zheng","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.mcna.2016.09.010_bib26","first-page":"71","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome","volume":"30","author":"Furlan","year":"2000","journal-title":"Adv Nephrol Necker Hosp"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mcna.2016.09.010_bib28","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/j.1538-7836.2009.03568.x","article-title":"IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura","volume":"7","author":"Ferrari","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2141.2005.05837.x","article-title":"Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura","volume":"132","author":"Coppo","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.mcna.2016.09.010_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.57.061804.084505","article-title":"Current concepts in thrombotic thrombocytopenic purpura","volume":"57","author":"Tsai","year":"2006","journal-title":"Annu Rev Med"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0002-9343(00)00697-5","article-title":"Improve survival with plasma exchange thrombotic thrombopenic purpura-hemolytic uremic syndrome","volume":"110","author":"Kaplan","year":"2001","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.mcna.2016.09.010_bib34","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1182\/blood.V91.8.2839.2839_2839_2846","article-title":"Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura","volume":"91","author":"Furlan","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jca.21302","article-title":"Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research","volume":"29","author":"Sarode","year":"2014","journal-title":"J\u00a0Clin Apher"},{"issue":"11","key":"10.1016\/j.mcna.2016.09.010_bib36","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.mcna.2016.09.010_bib37","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How I treat refractory thrombotic thrombocytopenic purpura","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.2830410119","article-title":"Successful treatment of thrombotic thrombocytopenic purpura with high-dose corticosteroid","volume":"41","author":"Toyoshige","year":"1992","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.mcna.2016.09.010_bib40","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib41","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","article-title":"Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura","volume":"8","author":"McDonald","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib42","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases","volume":"106","author":"Fakhouri","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1537-2995.2007.01530.x","article-title":"Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006","volume":"48","author":"Nguyen","year":"2008","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib44","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2007.06819.x","article-title":"Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity","volume":"139","author":"Cataland","year":"2007","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.mcna.2016.09.010_bib45","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib46","first-page":"349","article-title":"Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura?","volume":"53","author":"Dubois","year":"2010","journal-title":"Can J Surg"},{"issue":"24","key":"10.1016\/j.mcna.2016.09.010_bib47","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM197806152982407","article-title":"Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia","volume":"298","author":"Upshaw","year":"1978","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/humu.21143","article-title":"ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura","volume":"31","author":"Lotta","year":"2010","journal-title":"Hum Mutat"},{"issue":"8","key":"10.1016\/j.mcna.2016.09.010_bib49","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.mph.0000135284.85292.2c","article-title":"Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency","volume":"26","author":"Schiff","year":"2004","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2006.06264.x","article-title":"The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura","volume":"135","author":"Scully","year":"2006","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.mcna.2016.09.010_bib51","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","article-title":"Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura","volume":"89","author":"Furlan","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib52","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood-2002-08-2399","article-title":"von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP","volume":"101","author":"Schneppenheim","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mcna.2016.09.010_bib53","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00467-007-0616-x","article-title":"The thrombotic microangiopathies","volume":"23","author":"Copelovitch","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib54","first-page":"991","article-title":"Hemolytic uremic syndrome: an emerging health risk","volume":"74","author":"Razzaq","year":"2006","journal-title":"Am Fam Physician"},{"issue":"38\u201339","key":"10.1016\/j.mcna.2016.09.010_bib55","first-page":"905","article-title":"Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia","volume":"85","author":"Gasser","year":"1955","journal-title":"Schweiz Med Wochenschr"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib56","first-page":"65","article-title":"Shiga bacillus dysentery associated with marked leukocytosis and erythrocyte fragmentation","volume":"136","author":"Rahaman","year":"1975","journal-title":"Johns Hopkins Med J"},{"issue":"12","key":"10.1016\/j.mcna.2016.09.010_bib57","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM198303243081203","article-title":"Hemorrhagic colitis associated with a rare Escherichia coli serotype","volume":"308","author":"Riley","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib58","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1681\/ASN.2004100861","article-title":"Hemolytic uremic syndrome","volume":"16","author":"Noris","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib59","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.ajkd.2004.02.010","article-title":"Non-enteropathic hemolytic uremic syndrome: causes and short-term course","volume":"43","author":"Constantinescu","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"9464","key":"10.1016\/j.mcna.2016.09.010_bib60","first-page":"1073","article-title":"Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome","volume":"365","author":"Tarr","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib61","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2141.2008.07116.x","article-title":"Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison","volume":"141","author":"Karpac","year":"2008","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.mcna.2016.09.010_bib62","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2016.09.010_bib63","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.mcna.2016.09.010_bib64","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood-2010-02-271957","article-title":"Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice","volume":"116","author":"Huang","year":"2010","journal-title":"Blood"},{"issue":"9187","key":"10.1016\/j.mcna.2016.09.010_bib65","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0140-6736(99)01251-9","article-title":"Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak","volume":"354","author":"Dundas","year":"1999","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.mcna.2016.09.010_bib66","doi-asserted-by":"crossref","first-page":"908407","DOI":"10.4061\/2011\/908407","article-title":"Hemolytic uremic syndrome: new developments in pathogenesis and treatment","volume":"2011","author":"Boyer","year":"2011","journal-title":"Int J Nephrol"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib67","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mcna.2016.09.010_bib68","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"23","key":"10.1016\/j.mcna.2016.09.010_bib69","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib70","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1681\/ASN.V961126","article-title":"The pathogenesis and treatment of hemolytic uremic syndrome","volume":"9","author":"Kaplan","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.mcna.2016.09.010_bib71","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2007-08-106153","article-title":"Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation","volume":"111","author":"Stahl","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib72","first-page":"110","article-title":"Hypocomplementaemia due to a genetic deficiency of beta 1H globulin","volume":"46","author":"Thompson","year":"1981","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib73","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib74","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/01.ASN.0000115702.28859.A7","article-title":"Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases","volume":"15","author":"Dragon-Durey","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib75","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/01.ATV.9.6.802","article-title":"Complement receptors and regulatory proteins in human atherosclerotic lesions","volume":"9","author":"Seifert","year":"1989","journal-title":"Arteriosclerosi"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2010.155","article-title":"New insights into postrenal transplant hemolytic uremic syndrome","volume":"7","author":"Zuber","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.mcna.2016.09.010_bib77","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00467-003-1289-8","article-title":"The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children","volume":"18","author":"Loirat","year":"2003","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib78","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1160\/TH08-05-0322","article-title":"Autoantibodies in haemolytic uraemic syndrome (HUS)","volume":"101","author":"Skerka","year":"2009","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib79","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-6143.2009.02870.x","article-title":"Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T","volume":"10","author":"Waters","year":"2010","journal-title":"Am J Transplant"},{"issue":"9395","key":"10.1016\/j.mcna.2016.09.010_bib80","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"Familial haemolytic uraemic syndrome and an MCP mutation","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet (London, England)"},{"issue":"22","key":"10.1016\/j.mcna.2016.09.010_bib81","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome","volume":"100","author":"Richards","year":"2003","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib82","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"13","key":"10.1016\/j.mcna.2016.09.010_bib83","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fremeaux-Bacchi","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mcna.2016.09.010_bib84","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1681\/ASN.2005010103","article-title":"Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome","volume":"16","author":"Kavanagh","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib85","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ki.2009.472","article-title":"Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome","volume":"77","author":"Bienaime","year":"2010","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib86","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","article-title":"Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials","volume":"53","author":"Michael","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2016.09.010_bib87","series-title":"Therapy in nephrology & hypertension: a companion to Brenner & Rector's the kidney","first-page":"294","article-title":"Thrombotic microangiopathies","author":"Ruggenenti","year":"2008"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib88","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib89","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/j.ajkd.2004.10.018","article-title":"Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15","volume":"45","author":"Licht","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"18","key":"10.1016\/j.mcna.2016.09.010_bib90","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMc1001060","article-title":"Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome","volume":"362","author":"Zimmerhackl","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib91","doi-asserted-by":"crossref","first-page":"e1764","DOI":"10.1542\/peds.2013-1594","article-title":"Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome","volume":"133","author":"Diamante Chiodini","year":"2014","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib92","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib93","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0046-8177(92)90127-O","article-title":"A\u00a0congenital anomaly of vitamin B12 metabolism: a study of three cases","volume":"23","author":"Russo","year":"1992","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib94","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0022-3476(05)81967-5","article-title":"Cobalamin C defect associated with hemolytic-uremic syndrome","volume":"120","author":"Geraghty","year":"1992","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib95","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","article-title":"Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency","volume":"63","author":"Cornec-Le Gall","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib96","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib98","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1681\/ASN.2012090903","article-title":"DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN","volume":"24","author":"Ozaltin","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib99","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2622","article-title":"DGKE and atypical HUS","volume":"45","author":"Quaggin","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib101","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0889-8588(05)70348-8","article-title":"Thrombotic microangiopathies associated with drugs and bone marrow transplantation","volume":"10","author":"Moake","year":"1996","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib102","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1055\/s-2005-925474","article-title":"Drug-induced thrombotic microangiopathy","volume":"31","author":"Zakarija","year":"2005","journal-title":"Semin Thromb Hemost"},{"issue":"651","key":"10.1016\/j.mcna.2016.09.010_bib103","first-page":"14","article-title":"Acute intravascular haemolysis due to quinine","volume":"91","author":"Webb","year":"1980","journal-title":"N\u00a0Z Med J"},{"issue":"12","key":"10.1016\/j.mcna.2016.09.010_bib104","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.7326\/0003-4819-135-12-200112180-00008","article-title":"Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes","volume":"135","author":"Kojouri","year":"2001","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib105","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood.V80.1.241.241","article-title":"Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis","volume":"80","author":"Stroncek","year":"1992","journal-title":"Blood"},{"issue":"7\u20138","key":"10.1016\/j.mcna.2016.09.010_bib106","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1345\/aph.1G067","article-title":"Thrombotic thrombocytopenic purpura associated with quetiapine","volume":"39","author":"Huynh","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib107","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/14740330902942299","article-title":"Thrombotic microangiopathy associated with gemcitabine: rare but real","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib108","first-page":"715","article-title":"Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation","volume":"16","author":"Gharpure","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib109","first-page":"580","article-title":"Tacrolimus-associated hemolytic uremic syndrome: a case analysis","volume":"16","author":"Lin","year":"2003","journal-title":"J\u00a0Nephrol"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jjco\/27.2.115","article-title":"Mitomycin-C induced hemolytic uremic syndrome: a case report and literature review","volume":"27","author":"Wu","year":"1997","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"10.1016\/j.mcna.2016.09.010_bib111","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib112","first-page":"369","article-title":"Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature","volume":"6","author":"Saif","year":"2005","journal-title":"JOP"},{"issue":"24","key":"10.1016\/j.mcna.2016.09.010_bib113","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/jnci\/89.24.1895","article-title":"Gemcitabine-induced hemolytic uremic syndrome: a case report","volume":"89","author":"Brodowicz","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.mcna.2016.09.010_bib114","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","article-title":"A\u00a0review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib115","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1053\/ajkd.2002.35758","article-title":"Gemcitabine-associated hemolytic-uremic syndrome","volume":"40","author":"Walter","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2016.09.010_bib116","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0049-3848(02)00148-2","article-title":"Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes","volume":"107","author":"Barz","year":"2002","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib117","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jca.20213","article-title":"Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?","volume":"24","author":"Gore","year":"2009","journal-title":"J\u00a0Clin Apher"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib118","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib119","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bjh.12686","article-title":"Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy","volume":"164","author":"Starck","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib120","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","article-title":"Eculizumab and drug-induced haemolytic-uraemic syndrome","volume":"6","author":"Faguer","year":"2013","journal-title":"Clin Kidney J"},{"issue":"24","key":"10.1016\/j.mcna.2016.09.010_bib121","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","article-title":"Thrombotic thrombocytopenic purpura associated with clopidogrel","volume":"342","author":"Bennett","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"112","key":"10.1016\/j.mcna.2016.09.010_bib122","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2008.613","article-title":"Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008)","author":"Zakarija","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib123","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib124","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s002770050012","article-title":"Thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome (TTP\/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases","volume":"79","author":"Dervenoulas","year":"2000","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib125","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1473-0502(02)00020-4","article-title":"Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver","volume":"27","author":"Daly","year":"2002","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib127","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00003495-200969020-00004","article-title":"Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment","volume":"69","author":"Choi","year":"2009","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.mcna.2016.09.010_bib128","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31829807aa","article-title":"Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"96","author":"Laskin","year":"2013","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib130","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/trf.12859","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options","volume":"55","author":"Kim","year":"2015","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.mcna.2016.09.010_bib131","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/ndt\/11.7.1332","article-title":"Haemolytic uraemic syndrome following bone marrow transplantation. Case report and review of the literature","volume":"11","author":"Verburgh","year":"1996","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib132","first-page":"271","article-title":"Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome following bone marrow transplantation","volume":"16","author":"Sarode","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib133","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/bmt.2009.233","article-title":"Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange","volume":"45","author":"Kennedy","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.mcna.2016.09.010_bib134","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib135","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2007.06588.x","article-title":"Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab","volume":"137","author":"Au","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib136","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jca.2920060104","article-title":"Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome\/thrombotic thrombocytopenic purpura associated with bone marrow transplantation","volume":"6","author":"Silva","year":"1991","journal-title":"J\u00a0Clin Apher"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib137","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.bmt.1703414","article-title":"Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation","volume":"29","author":"Corti","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib138","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/1744-9987.12015","article-title":"Plasmapheresis-refractory transplantation-associated thrombotic microangiopathy successfully treated with pravastatin and limaprost alfadex","volume":"17","author":"Uesawa","year":"2013","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.mcna.2016.09.010_bib139","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/asheducation-2015.1.644","article-title":"Syndromes of thrombotic microangiopathy associated with pregnancy","volume":"2015","author":"George","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib140","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.clp.2004.06.007","article-title":"Imitators of severe pre-eclampsia\/eclampsia","volume":"31","author":"Sibai","year":"2004","journal-title":"Clin Perinatol"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib141","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ccc.2004.05.006","article-title":"Pregnancy-associated severe liver dysfunction","volume":"20","author":"Steingrub","year":"2004","journal-title":"Crit Care Clin"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib142","first-page":"1122","article-title":"Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.mcna.2016.09.010_bib143","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/01.ogx.0000146948.19308.c5","article-title":"HELLP syndrome: the state of the art","volume":"59","author":"Baxter","year":"2004","journal-title":"Obstet Gynecol Surv"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib144","first-page":"93","article-title":"Hypertensive disorders of pregnancy","volume":"78","author":"Leeman","year":"2008","journal-title":"Am Fam Physician"},{"issue":"9741","key":"10.1016\/j.mcna.2016.09.010_bib145","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","article-title":"Pre-eclampsia","volume":"376","author":"Steegers","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib146","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/ard.2003.019000","article-title":"The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women","volume":"64","author":"Le Thi Thuong","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.mcna.2016.09.010_bib147","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1471-0528.1997.tb14346.x","article-title":"The HELLP syndrome","volume":"104","author":"Geary","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib148","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/j.1523-1755.2005.00316.x","article-title":"Preeclampsia: a renal perspective","volume":"67","author":"Karumanchi","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2016.09.010_bib149","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2393-9-8","article-title":"The HELLP syndrome: clinical issues and management. A review","volume":"9","author":"Haram","year":"2009","journal-title":"BMC Pregnancy Childbirth"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib150","first-page":"266","article-title":"Maternal and neonatal outcome of pregnancies complicated with maternal HELLP syndrome","volume":"17","author":"Raval","year":"1997","journal-title":"J\u00a0Perinatol"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib151","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0002-9378(97)70005-X","article-title":"Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP (hemolysis, elevated liver enzymes, and thrombocytopenia) syndrome","volume":"177","author":"Martin","year":"1997","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib152","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.ajog.2005.07.037","article-title":"Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial","volume":"193","author":"Fonseca","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib153","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1471-0528.1995.tb09062.x","article-title":"Temporising management of severe pre-eclampsia with and without the HELLP syndrome","volume":"102","author":"Visser","year":"1995","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib154","doi-asserted-by":"crossref","first-page":"283.e1-8","DOI":"10.1016\/j.ajog.2007.10.797","article-title":"Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: a double-blind, placebo-controlled, randomized clinical trial","volume":"198","author":"Katz","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/107602960501100211","article-title":"The role of plasma exchange in HELLP syndrome","volume":"11","author":"Eser","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib156","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0002-9378(94)70063-X","article-title":"The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations","volume":"171","author":"Sullivan","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib157","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2002-02-0344","article-title":"Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura","volume":"100","author":"Bianchi","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib158","doi-asserted-by":"crossref","first-page":"385.e1-5","DOI":"10.1016\/j.ajog.2009.06.033","article-title":"Long-term maternal and subsequent pregnancy outcomes 5 years after hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome","volume":"201","author":"Habli","year":"2009","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib159","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00003081-199909000-00010","article-title":"Imitators of preeclampsia and eclampsia","volume":"42","author":"Egerman","year":"1999","journal-title":"Clin Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports","volume":"85","author":"Terrell","year":"2010","journal-title":"Am J Hematol"},{"issue":"5 Pt 1","key":"10.1016\/j.mcna.2016.09.010_bib161","first-page":"662","article-title":"The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy","volume":"91","author":"Dashe","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib162","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2012-08-448944","article-title":"How I treat thrombocytopenia in pregnancy","volume":"121","author":"Gernsheimer","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib163","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00003081-199906000-00020","article-title":"Diagnosis and management of thrombotic microangiopathies during pregnancy","volume":"42","author":"Esplin","year":"1999","journal-title":"Clin Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.mcna.2016.09.010_bib164","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1537-2995.2004.03422.x","article-title":"Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"44","author":"Vesely","year":"2004","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.mcna.2016.09.010_bib165","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood-2013-11-538900","article-title":"Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura","volume":"123","author":"Jiang","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib166","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib167","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"21","key":"10.1016\/j.mcna.2016.09.010_bib168","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood.V124.21.5019.5019","article-title":"Pregnancy-associated atypical hemolytic uremic syndrome (aHUS), treated with eculizumab","volume":"124","author":"Mandala","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mcna.2016.09.010_bib169","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib170","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0736-4679(99)00063-3","article-title":"Acute fatty liver of pregnancy","volume":"17","author":"Jwayyed","year":"1999","journal-title":"J\u00a0Emerg Med"},{"issue":"2","key":"10.1016\/j.mcna.2016.09.010_bib171","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0146-0005(98)80045-1","article-title":"Acute fatty liver of pregnancy","volume":"22","author":"Bacq","year":"1998","journal-title":"Semin Perinatol"},{"issue":"4","key":"10.1016\/j.mcna.2016.09.010_bib172","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/01.AOG.0000258281.22296.de","article-title":"Imitators of severe preeclampsia","volume":"109","author":"Sibai","year":"2007","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib173","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1155\/2006\/638131","article-title":"Acute fatty liver of pregnancy","volume":"20","author":"Ko","year":"2006","journal-title":"Can J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib174","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1056\/NEJM198508083130606","article-title":"Acute fatty liver of pregnancy","volume":"313","author":"Kaplan","year":"1985","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mcna.2016.09.010_bib175","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/01443619750113320","article-title":"Acute fatty liver of pregnancy","volume":"17","author":"Ranjan","year":"1997","journal-title":"J\u00a0Obstet Gynaecol"},{"issue":"11","key":"10.1016\/j.mcna.2016.09.010_bib176","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/ATVBAHA.115.306014","article-title":"Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura","volume":"35","author":"Tersteeg","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib177","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2016.09.010_bib178","first-page":"1","article-title":"Abstracts of the 62nd Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis May 25-28, 2016","volume":"14","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib179","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMe1515876","article-title":"Von Willebrand factor\u2013a new target for TTP treatment?","volume":"374","author":"Veyradier","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2016.09.010_bib180","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2016.09.010_bib181","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.mcna.2016.09.010_bib182","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mcna.2016.09.010_bib183","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/trf.12614","article-title":"Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report","volume":"54","author":"Yates","year":"2014","journal-title":"Transfusion"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712516373618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712516373618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T12:37:03Z","timestamp":1718973423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712516373618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":183,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0025712516373618"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2016.09.010","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syndromes of Thrombotic Microangiopathy","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2016.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}